{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009706","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.942950+00:00","generated_at":"2026-06-25T18:10:58.026379+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aura Biosciences Q1 2022 net loss $12.8M; cash $133.3M; AU-011 pivotal trial in 2H 2022","bullets":["Net loss of $12.8M in Q1 2022 compared to $5.9M in Q1 2021; cash and marketable securities $133.3M, sufficient into 2024.","R&D expenses $8.3M (up from $4.2M) and G&A $4.5M (up from $1.7M), driven by manufacturing and public company costs.","Plan to initiate pivotal trial for AU-011 in choroidal melanoma in 2H 2022; European Commission granted Orphan Drug Designation for uveal melanoma.","IND submission for choroidal metastases and Phase 1 trial in NMIBC expected in 2H 2022, with initial data in 2023.","Preclinical data at ASCO and AACR show AU-011's broad tumor targeting and combination potential with checkpoint inhibitors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009706","json":"https://secwatch.observer/filing/0000950170-22-009706.json","markdown":"https://secwatch.observer/filing/0000950170-22-009706.md","text":"https://secwatch.observer/filing/0000950170-22-009706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017022009706/0000950170-22-009706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017022009706/aura-20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:10:58.026379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}